Karyopharm Therapeutics Inc.

  • Director, Accounting and Reporting

    Job Locations US-MA-Newton
    Job ID
    # of Openings
    General & Administrative
    Regular Full-Time
  • Responsibilities

    • Lead the preparation and issuance of the financial statements with the SEC (Form 10K and Form 10Q) and assist with other filings.
    • Lead the preparation of workpapers supporting SEC financial filings including financial statements, footnote disclosures, MD&A, etc.
    • Analyze and review Financial Statements and other financial information to conclude on accuracy and/or identify and resolve issues for financial reporting/US GAAP/compliance.
    • Analyze and review XBRL mapping / tagging of financial statements and footnote disclosures
    • Analyze and prepare financial sections of Proxy Statement and assist with overall review of filing.
    • Lead the development and ultimate management of various revenue policies and procedures including government pricing, gross-to-net recognition, interaction with third-party logistics (3PL) providers, collaboration agreements and royalty/milestone agreements
    • Oversee accounting for ASC 606 and on-going assessment, including developing related internal controls
    • Oversee grant and VAT accounting to determine status and appropriate treatment
    • Analyze effects of new accounting pronouncements and/or regulations (issued by FASB, IASB, AICPA, SEC)
    • Lead Sarbanes-Oxley section 404 compliance regarding internal controls over financial reporting
    • Support the Controller in developing accounting policies, procedures and implementation of new or amended accounting standards
    • Monitor consistency of financial data in all externally reported information
    • Review documentation of quarterly earnings releases, attachments and conference call scripts
    • Lead in the comprehensive evaluation of various transactions to ensure timely confirmation of the accuracy, completeness, validity and ultimate integrity of accounting transactions and reported financial statements.
    • Assist with other compliance activities
    • Assist and/or lead operational / accounting improvement initiatives through collaboration with accounting, operational and IT personnel and leadership
    • Provide oversight, review, and guidance to other members on the team to ensure accurate financial reporting, proper documentation standards, knowledge and skill development, and promote team unity in the collective goal of quality financial statements and information reports submitted in a timely manner.


    • Bachelor’s Degree in Accounting
    • Licensed CPA with demonstrated and proven success in application of US GAAP, financial analysis, consolidations, and SEC financial reporting
    • 7-10+ years of financial accounting experience with Big 4 or national public accounting firm and/or industry experience;
    • Strong experience with life sciences revenue recognition and stock-based compensation is required
    • Experienced in executing due diligence steps to ensure SEC filing integrity.
    • Proven ability to:
        • Meet various statutory deadlines under tight time constraints.
        • Effectively communicate complex messages to diverse audiences at all organizational levels, both verbally and in writing.
        • Proficiently access and manipulate data for creating financial analyses and other formal presentations.
        • Work independently and be able to solve non-recurring problems through strong leadership.
    • Proven ability to understand, interpret, and prepare key SEC filings, including, but not limited to, forms 10-K, 10-Q, 8-K, proxy statements, MD&A, footnote disclosures, etc. (inclusive of XBRL and EDGAR filing requirements)


    Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019.


    Reporting to the Corporate Controller, The Director of Accounting & Reporting provides leadership and technical guidance of accounting policy development and financial reporting within the Corporate Accounting department. The individual in this role is responsible for the verbal and written communication with senior leadership and external auditors for technical accounting, reporting, and accounting policies.  This individual will be heavily involved with any commercial finance activity and lead all technical accounting projects and related activities including product and license revenue recognition, inventory, COGS, stock-based compensation and oversee international accounting for our ex-U.S. subsidiaries.


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed